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Identity 
Note: This molecular cytogenetic subgroup of ALL is 
characterised by the presence of multiple copies of the 
RUNX1 (AML1) gene on a duplicated chromosome 
21q (Figure 1). Using metaphase FISH multiple 
RUNX1 signals are seen along the length of the  
duplicated 21q (Figure 2), while in interphase the 
signals are clustered together (Figure 3). G-banded 
cytogenetic analysis shows that the morphology of the 
duplicated chromosome 21q is heterogeneous between 
cases (Figure 4). Currently, FISH with probes directed 





Fig1 : Left: A metaphase showing an abnormal chromosome (whole chromosome paint 21) with multiple RUNX1 (red) and two normal 
ETV6 (TEL) signals. Middle: A metaphase showing multiple RUNX1 exon signals (red) along the length of an abnormal chromosome 21 
Right: Interphase cells showing clustering of the red RUNX1 and the two normal green ETV6 signals, using the LSI TEL-AML1 
translocation probe (Vysis). 
 
 
Partial G-banded karyograms showing heterogeneity in the morphology of the duplicated 21q. The normal chromosome 21 is always on 
the left. 
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Clinics and pathology 
Disease 
Acute lymphoblastic leukaemia: B-lineage 
immunophenotype (mostly common or Pre-B), FAB 
L1/L2. 
Epidemiology 
The estimated incidence in childhood ALL is 1-3%. 
The majority of patients tend to be older children or 
adolescents with nearly three-quarters of reported 
patients aged between 6 and 14 years old. A few young 
adults have also been reported but too few to estimate 
its incidence in this age group. No gender bias has been 
observed. 
Clinics 
Patients with this abnormality typically present with a 
low white cell count of <20x109L 
Prognosis 
The three year event free survival of the 25 patients 
treated on the UK MRC ALL97 trial was just 51% 
(95% C.I. 27%-71%) and hence represent a poor risk 
cytogenetic feature in childhood ALL. 
Cytogenetics 
Note: Although FISH with a probe to the RUNX1 
(AML1) gene is required to accurately identify this 
abnormality, the duplicated chromosome 21 is easily 
visible using conventional cytogenetics. The 
morphology of the abnormal chromosome 21 is highly 
heterogeneous presenting as a metacentric, acrocentric 
or ring chromosome (Figure 4). Prior to the identify of 
this abnormality by FISH many karyotypes were 
described as -21,+mar. 
The duplicated 21q is rarely the sole chromosomal 
abnormality. The karyotype is frequently complex, 
although no recurrent secondary abnormality has yet 
emerged. This abnormality does not occur with other 
primary chromosomal abnormalities in ALL e.g. 
t(12;21)(p13;q22) / ETV6-RUNX1, t(9;22)(q34;q11), 
t(1;19)(q23;p13) etc. However, a few cases of high 
hyperdiploidy have been reported. 
FISH has been instrumental in defining this 
abnormality and is essential for its accurate detection. 
Virtually all cases reported to date have been identified 
using the LSI TEL-AML1 translocation probe. 
However, any FISH probe directed to RUNX1 could be 
used. The identification of metaphases with multiple 
RUNX1 signals on a single chromosome 21 is the most 
accurate detection method. However, in the absence of 
metaphases the presence of multiple clustered RUNX1 
signals is also reliable. 
The current published definitions of amplification 
within the context of this abnormality are as follows: 
only included cases in which the abnormality had been 
visualised in metaphases and three or more RUNX1 
signals were seen on a single abnormal chromosome 
21, while others used the same definition when the 
abnormality was seen in metaphase. Additionally, they 
included cases which revealed only interphases with 
five or more RUNX1 signals. 
Genes involved and Proteins 
RUNX1 
Note: By definition the RUNX1 (AML1) gene is 
amplified in all these patients. Over-expression of 
RUNX1 or any of the other genes within the amplified 
region has yet to be established. 
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